E-News - May 2020
ALLIANCE RESEARCH IN SPOTLIGHT
2020 Virtual ASCO MEETING May 29-31
The 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) will convene virtually May 29-31. The ASCO meeting brings together oncology professionals from around the world. This year's meeting theme is "Unite and Conquer: Accelerating Progress Together." Studies spanning the spectrum of cancer prevention and care, from immunotherapy and precision medicine to survivorship, will be highlighted.
Each year, ASCO attendees learn from leading-edge scientific presentations, including papers and talks from Alliance researchers, as well as thousands of scientific abstracts and research news developments. At this year's conference, Alliance investigators will present more than 20 studies, sharing the latest findings on breast cancer, head and neck cancer, lung cancer, GI and GU cancers, along with cancer control research. The Alliance will be well-represented with researchers participating on panels, discussing new research and presenting posters.
Join the Twitter conversation at #ASCO20 and please include @ALLIANCE_org
Here's a snapshot of studies that Alliance researchers will be presenting:
Breast Cancer - Local/Regional/Adjuvant
A011106
ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106
Lead author: Cynthia X. Ma
Abstract: 504
Clinical trial information: NCT01953588
N9831
Value of CTS5 for Late Relapse Risk Assessment in Patients with Early Stage HER2+ Breast Cancer in the NCCTG N9831 (Alliance) Trial
Lead author: Tanmayi Pai
Abstract/Poster: 529 / 21
Clinical trial information: NCT00005970
Cancer Prevention, Risk Reduction, and Genetics
C50303
Association of CEP72 rs924607 with vincristine-induced peripheral neuropathy in patients with diffuse large B-cell lymphoma on Alliance/CALGB 50303
Lead author: Daniel
L. Hertz
Abstract: E13535
Central Nervous System
A071401
Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations
Lead author: Priscilla K. Brastianos
Abstract: 2502
Clinical trial information: NCT02523014
A071701
Alliance A071701: Genomically guided treatment trial in brain metastases
Lead author: Priscilla Brastianos
Abstract/Poster: TPS2573 / 64
Clinical trial information: NCT03994796
Developmental Therapeutics - Immunotherapy
A151804, 9767
Alliance A151804: Establishment of a national biorepository to advance studies of immune-related adverse events
Lead author: David Kozono
Abstract/Poster: TPS3154 / 218
Clinical trial information: NCT04242095
Gastrointestinal Cancer - Colorectal and Anal
C80405
Predictive and prognostic value of HER2 gene expression and HER2 amplification in patients with metastatic colorectal cancer (mCRC) enrolled in CALGB/SWOG 80405 (Alliance)
Lead author: Francesca Battaglin
Abstract/Poster: 4086 / 78
Clinical trial information: NCT00265850
C80405, N9741
Rural and urban disparities based on zip code of residence: Analyses of 834 and 2159 patients in NCCTG N9741 and CALGB 80405 (Alliance) trials respectively
Lead author: Midhun Malla
Abstract: E16076
Clinical trial information: NCT00003594 NCT00265850
C80702
Celecoxib in addition to standard adjuvant therapy with 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) in stage III colon cancer: Results from CALGB/SWOG 80702
Lead author: Jeffrey A. Meyerhardt
Abstract: 4003
Clinical trial information: NCT01150045
N0147
Tumor infiltrating lymphocytes and tumor budding refine prognostication in patients with low and high risk stage III colon cancers (NCCTG N0147) [Alliance]
Lead author: D. Sha
Abstract/Poster: 4065 / 57
C80702
Overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant (adj) oxaliplatin and fluoropyrimidine-based therapy for patients (pts) with stage III colon cancer (CC): Final results from the IDEA (International Duration Evaluation of Adj chemotherapy) collaboration
Lead author: Alberto F. Sobrero
Abstract: 4004
Clinical trial information: NCT01150045
Genitourinary Cancer - Kidney and Bladder
A031704
PDIGREE: An adaptive phase 3 trial of PD-inhibitor nivolumab and Ipilimumab (IPI-NIVO) with VEGF TKI cabozantinib (CABO) in metastatic untreated renal cell cancer (Alliance A031704)
Lead author: Tian Zhang
Abstract/Poster: TPS5100 / 169
Clinical trial information: NCT03793166
Health Services Research and Quality Improvement
AFT-39
Nurse, oncologist, and patient impressions of electronic symptom monitoring via patient-reported outcomes in community oncology practices: Qualitative results from the U.S. national PRO-TECT trial
Lead author: Ethan Basch
Abstract/Poster: 7044 / 316
Clinical trial information: NCT03249090
A151925, A091105, COMET-2
Composite grading algorithm for National Cancer Institute's PRO-CTCAE
Lead author: Amylou C. Dueck
Abstract/Poster: 7018 / 290
Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia
C51101
Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in Alliance 51101
Lead author: Tracy Batchelor
Abstract/Poster: 8042 / 375
Clinical trial information: NCT01511562
A041202
Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202
Lead author: Amy S. Ruppert
Abstract: E20004
Clinical trial information: NCT01886872
A051103, C50701, C50801, C50901, S0016, S0816
Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials
Lead author: Sarah C. Rutherford
Abstract/Poster: 8038 / 371
Clinical trial information: NCT00553501 NCT01145495 NCT01190449 NCT01286272 NCT01829568 NCT00822120 NCT00770224
Non-Small Cell Local/Regional/Small Cell/Other Thoracic Cancers
AFT-16
AFT-16: Phase II trial of atezolizumab before and after definitive chemoradiation for unresectable stage III NSCLC
Lead author: Helen J. Ross
Abstract/Poster: 9045 / 238
Clinical trial information: NCT03102242
A081105, A151216, A081801
ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high risk resected NSCLC (Alliance)
Lead author: Jacob Sands
Abstract/Poster: TPS9077 / 270
Clinical trial information: NCT02194738
Sarcoma
A091401
A multicenter phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401): Results of expansion cohorts
Lead author: James Chen
Abstract/Poster: 11511 /399
Clinical trial information: NCT02500797
A091304
A randomized phase II study of MLN0128 (M) versus pazopanib (P) in patients (pt) with advanced sarcoma (Alliance A091304)
Lead author: Matthew Ingham
Abstract/Poster: 11562 / 450
Clinical trial information: NCT02601209
Symptoms and Survivorship
Pilot
A pilot randomized, placebo-controlled, double-blind study of omega-3 fatty acids to prevent paclitaxel-associated acute pain syndrome
Lead author: Zoneddy Dayao
Abstract: E24115
Clinical trial information: NCT01821833
Randomized trial of a symptom monitoring intervention for hospitalized patients with advanced cancer. (NCT03396510)
Lead author: Ryan D. Nipp
Abstract/Poster: 12014 / 302
Clinical trial information: NCT03396510
A221101
A phase III randomized, double-blind placebo controlled study of armodafinil (nuvigil®) to reduce cancer-related fatigue in patients with high grade glioma (Alliance A221101)
Lead author: Alyx B. Porter
Abstract: 12007
Clinical trial information: NCT01781468
A191402CD
Decision aids for localized prostate cancer: Outcomes from an Alliance Research Base Cancer Care Delivery Research (CCDR) protocol - A191402CD
Lead author: Jon Tilburt
Abstract: e24176
Clinical trial information: NCT03103321
